Amrit Ray

Amrit Ray

Auto-generated profile, based on publicly available information

Amrit Ray

Research, Development and Medical, Upjohn Division, Pfizer Inc, Collegeville, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2005 in Human Reproduction
Verified
Journal Article
Open access
PDF file
PCP.G. Crosignani
P.G. Crosignani
ALA. Luciano
A. Luciano
ARA. Ray
A. Ray
ABA. Bergqvist
A. Bergqvist
BACKGROUND: A clinical study compared efficacy and safety of depot medroxyprogesterone acetate (DMPA) with leuprolide for endometriosis-associated pain. METHODS: This multicentre, 18 month, evaluator-blinded, comparator-controlled trial randomized 300 women with laparoscopically diagnosed endometriosis to 6 month treatment with subcutaneous injection of 104 mg/0.65 ml DMPA (DMPA-SC 104) every 3 months or leuprolide (3.75 mg monthly or 11.25 mg every 3 months), with 12 months post-treatment follow-up. Endpoints included patient response to treatment in five signs/symptoms (dysmenorrhoea, dyspareunia, pelvic pain, pelvic tenderness, induration) and changes in bone mineral density (BMD) and productivity at 6 and 18 months. RESULTS: DMPA-SC 104 and leuprolide produced equivalent (P < 0.02) reductions in at least four pain categories and significant (P < 0.001) improvements in composite score at months 6 and 18. At month 6, reductions in total hip and lumbar spine BMD were significantly less (P < 0.001) with DMPA-SC 104 versus leuprolide. BMD returned to pre-treatment levels 12 months post-treatment in the DMPA-SC 104 but not the leuprolide group. Total productivity also significantly (P≤0.05) improved in both groups at 6 and 18 months. CONCLUSIONS: DMPA-SC 104 reduces endometriosis-associated pain as effectively as leuprolide and improves productivity with significantly less BMD decline.

1 July 2020 in Journal of Multidisciplinary Healthcare
Verified
Journal Article
Open access
PDF file
AGAakash Ganju
Aakash Ganju
AGAlessandra C Goulart
Alessandra C Goulart
ARAmrit Ray
Amrit Ray
AMAnurita Majumdar
Anurita Majumdar
BJBarrett W Jeffers
Barrett W Jeffers
YWYuan-Pang Wang
Yuan-Pang Wang
Non-communicable diseases (NCDs) have been on the rise in low- and middle-income countries (LMICs) over the last few decades and represent a significant healthcare concern. Over 85% of “premature” deaths worldwide due to NCDs occur in the LMICs. NCDs are an economic burden on these countries, increasing their healthcare expenditure. However, targeting NCDs in LMICs is challenging due to evolving health systems and an emphasis on acute illness. The major issues include limitations with universal health coverage, regulations, funding, distribution and availability of the healthcare workforce, and availability of health data. Experts from across the health sector in LMICs formed a Think Tank to understand and examine the issues, and to offer potential opportunities that may address the rising burden of NCDs in these countries. This review presents the evidence and posits pragmatic solutions to combat NCDs.

1 July 2020 in Journal of Multidisciplinary Healthcare
Verified
Journal Article
Open access
PDF file
KZKelly Zou
Kelly Zou
JLJim Z Li
Jim Z Li
JIJoseph Imperato
Joseph Imperato
CPChandrashekhar N Potkar
Chandrashekhar N Potkar
NSNikuj Sethi
Nikuj Sethi
ARAmrit Ray
Amrit Ray
A vast quantity of real-world data (RWD) are available to healthcare researchers. Such data come from diverse sources such as electronic health records, insurance claims and billing activity, product and disease registries, medical devices used in the home, and applications on mobile devices. The analysis of RWD produces real-world evidence (RWE), which is clinical evidence that provides information about usage and potential benefits or risks of a drug. This review defines and explains RWD, and it also details how regulatory authorities are using RWD and RWE. The main challenges in harnessing RWD include collating and analyzing numerous disparate types or categories of available information including both structured (eg, field entries) and unstructured (eg, doctor notes, discharge summaries, social media posts) data. Although the use of artificial intelligence to capture, amalgamate, standardize, and analyze RWD is still evolving, it has the potential to support the increased use of RWE to improve global health and healthcare.

6 November 2020 in Health Services and Outcomes Research Methodology
Verified
Journal Article
Closed access
PDF file
KZKelly Zou
Kelly Zou
JLJim Z. Li
Jim Z. Li
LSLobna A. Salem
Lobna A. Salem
JIJoseph Imperato
Joseph Imperato
JEJon Edwards
Jon Edwards
ARAmrit Ray
Amrit Ray

1 January 2016 in Indian Journal of Nephrology
Verified
Journal Article
Open access
PDF file
KMK Mittal
K Mittal
PWP Wanjari
P Wanjari
RSR Sharma
R Sharma
ADAk Dey
Ak Dey
ARA Ray
A Ray
HTH Thakkar
H Thakkar
Official peer-reviewed open access publication Indian Association of Medical Microbiologists

22 July 2022
Verified
Book Chapter
Closed access
PDF file
KZKelly Zou
Kelly Zou
LSLobna A. Salem
Lobna A. Salem
ARAmrit Ray
Amrit Ray
In the final chapter of the book “Real World Evidence in a Patient Centric Digital Era,” we present overall visions for the future of patient-centric and data-driven healthcare. Specifically, we emphasize harnessing real-world data (RWD) to gain real-world evidence (RWE) in present-day medical research, particularly in addressing noncommunicable diseases (NCDs) and offer ideas on a future vision for healthcare in which the community can follow the emerging trends in RWE to make an impact on individual patients and public health. As final remarks, we reiterate the importance of the role of the patient in evidence-based research.